MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-DL-02-0005770
Rivpra Formulation Private Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹215.35 Cr
▼ 7% YoY
Net profit · FY 2025
₹21.11 Cr
Net margin 9.8%
EBITDA · FY 2025
₹31.29 Cr
EBITDA margin 14.5%
Authorised capital
₹4 Cr
Registered with MCA
Paid-up capital
₹4 Cr
Issued & subscribed
Open charges
₹59 Cr
Satisfied ₹7.67 Cr
Company age
21 yrs
Est. 2005
Employees · EPFO
91
Provident fund records
About Rivpra Formulation Private Limited
Data last updated:
Rivpra Formulation Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 November 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24232DL2005PTC142755. Its GSTIN is 07AADCR2652M1Z5 (Delhi). The company holds 7 GST registrations, of which 6 are active.
The company has an authorised share capital of ₹4 Cr and a paid-up capital of ₹4 Cr. It is led by directors Vibhor Rastogi and Ram Prakash Rastogi.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 5 Manak Vihar Opp.Yojna Vihar, New Delhi, Delhi, India – 110092.
As per the financials filed for FY 2025, the company reported a revenue of ₹215.35 Cr, a decline of 7% compared to the previous year. For the same year it recorded a net profit of ₹21.11 Cr (net margin 9.8%) and EBITDA of ₹31.29 Cr (EBITDA margin 14.5%). Revenue has grown at a compounded annual rate (CAGR) of 7% over three years and 14% over five years.
The company has about 91 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Oteria and Rivpra Formulation. As per MCA filings, the company has open charges of ₹59 Cr and satisfied charges of ₹7.67 Cr on record. Court records list 35 cases involving the company, including 9 filed by the company and 26 filed against it; 21 cases are pending. The company has 9 deals on record (5 funding rounds, 4 secondary share transfers), with disclosed funding of ₹3.99 Cr; the latest was in March 2022. Its 6 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 3 smaller; the largest is Naprod Life Sciences Private Limited with revenue of ₹219.65 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 11 overdue payments to 11 micro and small suppliers.
Rivpra Formulation Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-02-0005770). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website rivpraformulation.com.
Company details
CIN U24232DL2005PTC142755
Registration Number 142755
Incorporation Date 21 November 2005
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-DL-02-0005770
Recognitions & Rankings of Rivpra Formulation
Contact details
Rivpra Formulation Private Limited's registered office is in New Delhi, Delhi. Its website is rivpraformulation.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address5 Manak Vihar Opp.Yojna Vihar, New Delhi, Delhi, India – 110092
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Rivpra Formulation Private Limited, buy the company report.
Comprehensive company report
Rivpra Formulation Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Rivpra Formulation operates two associated brands: Oteria and Rivpra Formulation. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Skincare products aligned with skin's natural rhythms for effective daily care. | oteria.com | |
| Manufacturer of generic tablets, capsules, and liquid | rivpraformulation.com |
Business activity
The main business activity of Rivpra Formulation is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Rivpra Formulation Private Limited, buy the company report.
Financials of Rivpra Formulation Private Limited
FY 2024 filings availableRivpra Formulation Private Limited reported revenue of ₹215.35 Cr (down 7% YoY) for FY 2025.
Revenue · FY 2025
₹215.35 Cr ▼ 7%
Net profit · FY 2025
₹21.11 Cr margin 9.8%
EBITDA · FY 2025
₹31.29 Cr margin 14.5%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 7%
3 years · compounded
▲ 7%
5 years · compounded
▲ 14%
EBITDA CAGR growth
1 year
▲ 24%
3 years · compounded
▲ 16%
5 years · compounded
▲ 14%
Revenue fell 7% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 14%. EBITDA rose 24% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹31.29 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹21.11 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 14.5% | ||||
| Net Profit Margin | 9.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Rivpra Formulation Private Limited, buy the company report.
Board of directors of Rivpra Formulation Private Limited
Rivpra Formulation has 2 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vibhor Rastogi | Director | 21 Nov 2005 | 20 Years 11 Months | Current |
| Ram Prakash Rastogi | Director | 28 Mar 2015 | 11 Years 6 Months | Current |
Peer comparison
Rivpra Formulation Private Limited is compared with the 6 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Naprod Life Sciences Private Limited | ₹219.65 Cr (FY 2025) | 1.0% | Mumbai, Maharashtra, India | |||
| Makson Healthcare Private Limited | ₹217.91 Cr (FY 2024) | -2.0% | Mandideep, Madhya Pradesh, India | |||
| Relax Pharmaceuticals Private Limited | ₹215.76 Cr (FY 2024) | 29.0% | Saharanpur, Uttar Pradesh, India | |||
| Rivpra Formulation Private Limitedthis company | ₹215.35 Cr (FY 2025) | ₹21.11 Cr | 9.8% | -7.0% | 91 | New Delhi, Delhi, India |
| Speciality Organics Pvt Ltd | ₹214.1 Cr (FY 2025) | 34.0% | Mandideep, Madhya Pradesh, India | |||
| Vins Bioproducts Limited | ₹210.48 Cr (FY 2025) | 34.0% | Maheswaram, Telangana, India | |||
| Kilitch Drugs (India) Limited. | ₹209.48 Cr (FY 2025) | 32.0% | Thane, Maharashtra, India |
To see the full peer comparison of Rivpra Formulation Private Limited, buy the company report.
Auditor
Rivpra Formulation Private Limited is audited by Jitender R Deo & Company for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Jitender R Deo & Company | FY 2024 | 0019127N |
Shareholding
The shareholding of Rivpra Formulation Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Rivpra Formulation Private Limited, buy the company report.
Charges & borrowings
Open charges
₹59 Cr
Satisfied charges
₹7.67 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 02 Apr 2024 | 100934272 | Hdfc Bank Limited | ₹18 Cr | Open | |
| 03 May 2023 | 100712873 | Others | ₹5 Cr | Open | |
| 13 Mar 2023 | 100713553 | Others | ₹5 Cr | Open | |
| 22 Mar 2016 | 100022551 | Hdfc Bank Limited | ₹31 Cr | Open | |
| 09 May 2019 | 100263893 | Others | ₹8 Lakh | Satisfied |
To see the full charge records of Rivpra Formulation Private Limited, buy the company report.
Total charge records: 8 View all charges
Deals & funding
Rivpra Formulation Private Limited has 9 deals on record (5 funding rounds, 4 secondary share transfers), with disclosed funding of ₹3.99 Cr; the latest was in March 2022.
Total deals
9
Funding rounds
5
Secondary share transfers
4
Disclosed funding
₹3.99 Cr
Deals on record (5 of 9)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
| Aug 2019 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
| May 2018 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Rajesh Kumar Rastogi HUF, an individual |
| Mar 2017 | Funding round | ₹25 Lakh | Investors: 2 individuals |
| May 2015 | Funding round | ₹1.75 Cr | Investors: 3 individuals |
To see the full deal history of Rivpra Formulation Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Rivpra Formulation Private Limited has 35 court cases on record: 9 filed by Rivpra Formulation, 26 filed against it. 21 cases are pending and 14 are disposed.
Total cases
35
Filed by the company
9
Filed against the company
26
Pending
21
Disposed
14
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 26 | 22 | 16 |
| High courts | 8 | 3 | 5 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 35)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court | Court case (COMIP) | Filed against the company by Ajanta Pharma Limited | Pending |
| District court, Dehradun, Uttarakhand | Commercial suit | Filed against the company by Boehringer Ingelheim India Pvt. Ltd. and 1 other | Pending |
| District court, East, Delhi | Criminal case | Filed by the company against Taru Pharma Pvt Ltd. | Disposed |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by an individual | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Interim or miscellaneous application | Filed against the company by Union of India Represented by Chinmaykumar H Patel | Pending |
To see the full case history of Rivpra Formulation Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Rivpra Formulation Private Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 11 overdue payments to 11 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 11)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Biogenetic Healthcare | |||
| an individual supplier | |||
| Indo Pack Limited | |||
| S.K.Industries | |||
| Rakshit Pharmaceuticals Limited |
To see the full MSME payment records of Rivpra Formulation Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Rivpra Formulation Private Limited has a workforce of 91 employees on its EPFO records as of Mar 21, 2025, across 1 active EPFO establishment.
Employee count
91
Active EPFO establishments
1
Employee growth
12.35%
GST
Rivpra Formulation has 7 GST registrations: 6 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
7
Active
6
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AADCR2652M1Z5 | Delhi | Active | 21 Jul 2017 |
| 05AADCR2652M1Z9 | Uttarakhand | Active | 01 Jul 2017 |
| 09AADCR2652M1Z1 | Uttar Pradesh | Active | 09 Jul 2018 |
| 23AADCR2652M1ZB | Madhya Pradesh | Active | 10 May 2022 |
To see the full GST registrations and return filing status of Rivpra Formulation Private Limited, buy the company report.
Recent activity
Rivpra Formulation Private Limited has 6 board changes on record since 2005: 3 appointments and 3 cessations. The latest: Anand Kumar Singh was appointed as Manager on 11 Jan 2024.
Charges
A charge with Hdfc Bank Limited of Rs. 31.00 Cr registered on 22 Mar 2016 with Charge ID 100022551 was modified on 04 Jul 2025.
AGM
Rivpra Formulation Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 18.00 Cr with Charge ID 100934272 was registered on 02 Apr 2024.
Filing
Rivpra Formulation Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.
Appointed
Anand Kumar Singh was appointed as Manager.
Charges
A charge with Others amounted to Rs. 5.00 Cr with Charge ID 100712873 was registered on 03 May 2023.
Charges
A charge with Others amounted to Rs. 5.00 Cr with Charge ID 100713553 was registered on 13 Mar 2023.
Charges
A charge registered on 09 May 2019 via Charge ID 100263893 with Others was fully satisfied on 09 Dec 2019.
Charges
A charge with Others amounted to Rs. 0.08 Cr with Charge ID 100263893 was registered on 09 May 2019.
Ceased
Neelima Rastogi ceased to be Director.
Ceased
Rajesh Kumar Rastogi ceased to be Director.
Charges
A charge registered on 14 Mar 2013 via Charge ID 10424875 with Kotak Mahindra Bank Limited was fully satisfied on 08 Nov 2016.
10 earlier events are in the company report.
Frequently asked questions
Rivpra Formulation is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 November 2005 (21+ years old) and is registered under CIN U24232DL2005PTC142755.
Rivpra Formulation has 2 current directors:
- Vibhor Rastogi - Director
- Ram Prakash Rastogi - Director
The latest financial statements of Rivpra Formulation on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Rivpra Formulation is 07AADCR2652M1Z5, registered in Delhi. The company has 7 GST registrations in all, of which 6 are active and 1 is cancelled or inactive. Other active GSTINs include 05AADCR2652M1Z9 (Uttarakhand), 09AADCR2652M1Z1 (Uttar Pradesh), 23AADCR2652M1ZB (Madhya Pradesh).
The CIN (Corporate Identification Number) of Rivpra Formulation is U24232DL2005PTC142755. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Rivpra Formulation has 35 court cases on record: 9 filed by the company and 26 filed against it. 21 are pending. Most are in the district courts.
Rivpra Formulation was incorporated on 21 November 2005, making it 21+ years old. It is registered with the Registrar of Companies, Delhi.
Rivpra Formulation has 9 deals on record (5 funding rounds, 4 secondary share transfers), with disclosed funding of ₹3.99 Cr; the latest was in March 2022.
The peers of Rivpra Formulation by revenue are Naprod Life Sciences Private Limited, Makson Healthcare Private Limited, Relax Pharmaceuticals Private Limited, Speciality Organics Pvt Ltd, Vins Bioproducts Limited and 1 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Anand Kumar Singh was appointed as Manager on 11 Jan 2024. Neelima Rastogi ceased to be Director on 31 May 2018. Rajesh Kumar Rastogi ceased to be Director on 31 May 2018. Rivpra Formulation has 6 board changes on record in total.
Yes, Rivpra Formulation is registered as a medium enterprise under Udyam registration (number: UDYAM-DL-02-0005770).
Rivpra Formulation has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 11 overdue payments to 11 micro and small suppliers. The latest return was filed on 09 Jun 2019.